Pegylated liposomal doxorubicin in ovarian cancer.
Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.
Green
Andrew E
AE
Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Cleveland Clinic, Cleveland, OH 44195, USA.
Rose
Peter G
PG
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000737:chemistry; D004317:Doxorubicin / Q000008:administration & dosage* / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D006801:Humans; D008081:Liposomes / Q000737:chemistry*; D050997:Nanomedicine / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000737:chemistry*
D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin
J Clin Oncol. 1995 Jul;13(7):1777-85
7602367
Cancer. 2002 Nov 15;95(10):2223-9
12412177
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:79-85
16515572
Cancer. 2003 Aug 1;98(3):610-7
12879480
Tumori. 2003 May-Jun;89(3):237-49
12908776
Anticancer Res. 2003 Jul-Aug;23(4):3543-8
12926104
Gynecol Oncol. 2003 Aug;90(2 Pt 2):S1-7
12927999
Ann Oncol. 2003 Sep;14(9):1406-11
12954580
Gynecol Oncol. 2003 Sep;90(3):610-8
13678734
Anticancer Drugs. 2003 Sep;14(8):633-8
14501385
Br J Cancer. 2003 Oct 6;89(7):1180-4
14520442
Ann Oncol. 2004 Mar;15(3):440-9
14998846
Gynecol Oncol. 2004 Aug;94(2):320-4
15297168
Gynecol Oncol. 2004 Aug;94(2):409-15
15297181
Gynecol Oncol. 2004 Oct;95(1):1-8
15385103
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):65-70
16445612
Oncology. 2004;67(3-4):183-6
15557776
Gynecol Oncol. 2006 Jun;101(3):423-8
16325239
Gynecol Oncol. 2006 Aug;102(2):226-9
16443259
Oncology. 2004;67(3-4):243-9
15557785
Science. 2005 Jan 7;307(5706):58-62
15637262
Ann Oncol. 2005 Feb;16(2):300-6
15668288
Tumori. 2004 Nov-Dec;90(6):556-61
15762356
Oncologist. 2005 Mar;10(3):205-14
15793224
Gynecol Oncol. 2005 May;97(2):374-8
15863132
Br J Cancer. 2005 Jul 11;93(1):46-53
15942626
Gynecol Oncol. 2005 Aug;98(2):267-73
15975643
Anticancer Res. 2005 Jul-Aug;25(4):3103-8
16080573
Clin Cancer Res. 2005 Aug 15;11(16):5912-9
16115933
Oncology. 2005;69(4):348-53
16293974
Cancer Invest. 2005;23(8):665-70
16377584
Gynecol Oncol. 2006 Feb;100(2):318-23
16239023
Int J Oncol. 1999 Dec;15(6):1233-8
10568833
Am J Clin Oncol. 2000 Jun;23(3):297-300
10857898
J Clin Oncol. 2000 Sep;18(17):3093-100
10963637
Gynecol Oncol. 2000 Sep;78(3 Pt 1):369-72
10985896
Gynecol Oncol. 2001 May;81(2):206-12
11330951
J Clin Oncol. 2001 Jul 15;19(14):3312-22
11454878
Gynecol Oncol. 2001 Aug;82(2):323-8
11531287
Clin Cancer Res. 2001 Oct;7(10):3040-6
11595693
Am J Clin Dermatol. 2000 Jul-Aug;1(4):225-34
11702367
Drug Saf. 2001;24(12):903-20
11735647
Gynecol Oncol. 2002 Apr;85(1):136-9
11925133
Br J Cancer. 2002 May 6;86(9):1379-84
11986767
Eur J Cancer. 2002 Oct;38(15):1992-7
12376203
J Clin Oncol. 1997 Mar;15(3):987-93
9060537